760
Views
44
CrossRef citations to date
0
Altmetric
Research Article

Effects of Cognitive Impairment on Substance Abuse Treatment Attendance: Predictive Validation of a Brief Cognitive Screening Measure

, Ph.D., , Ph.D., , Sc.D., , Ph.D., , LICSW, , R.N., M.S.N. & , M.D. show all
Pages 246-250 | Published online: 26 Mar 2012
 

Abstract

Background and objectives: Neuropsychological impairment among patients with substance use disorders (SUDs) contributes to poorer treatment processes and outcomes. However, neuropsychological assessment is typically not an aspect of patient evaluation in SUD treatment programs because it is prohibitively time and resource consuming. In a previous study, we examined the concurrent validity, classification accuracy, and clinical utility of a brief screening measure, the Montreal Cognitive Assessment (MoCA), in identifying cognitive impairment among SUD patients. To provide further evidence of criterion-related validity, MoCA classification should optimally predict a clinically relevant behavior or outcome among SUD patients. The purpose of this study was to examine the validity of the MoCA in predicting treatment attendance. Methods: We compared previously collected clinical assessment data on 60 SUD patients receiving treatment in a program of short duration and high intensity to attendance data obtained via medical chart review. Results: Though the proportion of therapy sessions attended did not differ between groups, cognitively impaired subjects were significantly less likely than unimpaired subjects to attend all of their group therapy sessions. Conclusion: These results complement our previous findings by providing further evidence of criterion-related validity of the MoCA in predicting a clinically relevant behavior (i.e., perfect attendance) among SUD patients. Scientific significance: The capacity of the MoCA to predict a clinically relevant behavior provides support for its validity as a brief cognitive screening measure.

ACKNOWLEDGMENT

This study was supported by NIDA grant 1R03DA024126 (Copersino), 1K23DA027045 (Copersino), and 5K24DA022288 (Weiss).

Declaration of Interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.